These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34234295)

  • 1. Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML.
    Krieger E; Qayyum R; Keating A; Toor A
    Bone Marrow Transplant; 2021 Nov; 56(11):2714-2722. PubMed ID: 34234295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Killer Immunoglobulin-Like Receptor-Ligand Interactions Predict Clinical Outcomes following Unrelated Donor Transplantations.
    Krieger E; Sabo R; Moezzi S; Cain C; Roberts C; Kimball P; Chesney A; McCarty J; Keating A; Romee R; Wiedl C; Qayyum R; Toor A
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):672-682. PubMed ID: 31676338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.
    Krieger E; Qayyum R; Toor A
    Br J Haematol; 2024 May; 204(5):1935-1943. PubMed ID: 38442905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
    Cooley S; Trachtenberg E; Bergemann TL; Saeteurn K; Klein J; Le CT; Marsh SG; Guethlein LA; Parham P; Miller JS; Weisdorf DJ
    Blood; 2009 Jan; 113(3):726-32. PubMed ID: 18945962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.
    Fein JA; Shouval R; Krieger E; Spellman SR; Wang T; Baldauf H; Fleischhauer K; Kröger N; Horowitz M; Maiers M; Miller JS; Mohty M; Nagler A; Weisdorf D; Malmberg KJ; Toor AA; Schetelig J; Romee R; Koreth J
    Blood Adv; 2024 Feb; 8(3):581-590. PubMed ID: 38052043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.
    Rangarajan HG; Pereira MSF; Brazauskas R; St Martin A; Kussman A; Elmas E; Verneris MR; Gadalla SM; Marsh SGE; Paczesny S; Spellman SR; Lee SJ; Lee DA
    Transplant Cell Ther; 2021 Nov; 27(11):926.e1-926.e10. PubMed ID: 34407489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.
    Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Cereb N; Haagenson MD; Spellman SR; Lee SJ; Guethlein LA; Parham P; Miller JS; Cooley SA
    Biol Blood Marrow Transplant; 2019 May; 25(5):949-954. PubMed ID: 30594542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
    Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
    J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
    Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
    Front Immunol; 2020; 11():584520. PubMed ID: 33542712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.
    Weisdorf D; Cooley S; Wang T; Trachtenberg E; Vierra-Green C; Spellman S; Sees JA; Spahn A; Vogel J; Fehniger TA; Woolfrey AE; Devine SM; Ross M; Waller EK; Sobecks RM; McGuirk J; Oran B; Farag SS; Shore T; Van Besien K; Marsh SGE; Guethlein LA; Parham P; Miller JS
    Blood Adv; 2020 Feb; 4(4):740-754. PubMed ID: 32092137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular relapse monitoring reveals the domination of impaired NK cell education over impaired inhibition in missing KIR-ligand recognition in patients after unrelated hematopoietic stem cell transplantation for malignant diseases.
    Nowak J; Witkowska A; Rogatko-Koroś M; Malinowska A; Graczyk-Pol E; Nestorowicz-Kałużna K; Flaga A; Szlendak U; Wnorowska A; Gawron A
    HLA; 2024 Feb; 103(2):e15364. PubMed ID: 38312022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor
    Schetelig J; Baldauf H; Heidenreich F; Hoogenboom JD; Spellman SR; Kulagin A; Schroeder T; Sengeloev H; Dreger P; Forcade E; Vydra J; Wagner-Drouet EM; Choi G; Paneesha S; Miranda NAA; Tanase A; de Wreede LC; Lange V; Schmidt AH; Sauter J; Fein JA; Bolon YT; He M; Marsh SGE; Gadalla SM; Paczesny S; Ruggeri A; Chabannon C; Fleischhauer K
    Front Immunol; 2024; 15():1350470. PubMed ID: 38629074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.
    Cooley S; Weisdorf DJ; Guethlein LA; Klein JP; Wang T; Marsh SG; Spellman S; Haagenson MD; Saeturn K; Ladner M; Trachtenberg E; Parham P; Miller JS
    J Immunol; 2014 May; 192(10):4592-600. PubMed ID: 24748496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
    Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.
    Sobecks RM; Wang T; Askar M; Gallagher MM; Haagenson M; Spellman S; Fernandez-Vina M; Malmberg KJ; Müller C; Battiwalla M; Gajewski J; Verneris MR; Ringdén O; Marino S; Davies S; Dehn J; Bornhäuser M; Inamoto Y; Woolfrey A; Shaw P; Pollack M; Weisdorf D; Milller J; Hurley C; Lee SJ; Hsu K
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1589-96. PubMed ID: 25960307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
    Venstrom JM; Pittari G; Gooley TA; Chewning JH; Spellman S; Haagenson M; Gallagher MM; Malkki M; Petersdorf E; Dupont B; Hsu KC
    N Engl J Med; 2012 Aug; 367(9):805-16. PubMed ID: 22931314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How important is NK alloreactivity and KIR in allogeneic transplantation?
    Shaffer BC; Hsu KC
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML.
    Shaffer BC; Le Luduec JB; Park S; Devlin S; Archer A; Davis E; Cooper C; Nhaissi M; Suri B; Wells D; Tamari R; Papadopoulos E; Jakubowski AA; Giralt S; Hsu KC
    Blood Adv; 2021 Apr; 5(7):2003-2011. PubMed ID: 33843984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.